Media alert - Montreal to be the epicenter of research & treatment news in multiple sclerosis at events scheduled September 16 - 20, 2008



    MONTREAL, Sept. 16 /CNW Telbec/ - WHAT: Starting with a consumer program
focused on Living With MS, Sept. 16 at 9.00 - 17.00 in LE CENTRE SHERATON and
moving on to the scientific proceedings on treatment and research in MS,
Sept. 17-20 at the PALAIS DES CONGRES DE MONTREAL, the World MS Congress
offers several historic firsts.
    With its nearly 5200 participants including clinicians, clinical
researchers and basic scientists from 55 countries, it is the largest MS
scientific conference ever held. It also marks the first time that the
Americas Committee, the European Committee and the Latin American Committee
for Treatment and Research in MS have met jointly. The first world Atlas on MS
will also be introduced.

    WHY: Including late breaking news, there will be 45 platform and
900 poster presentations covering the most important topics in the field of
multiple sclerosis, plus 10 teaching courses. These presentations will be made
by some of the greatest scientific leaders in the field of MS research and
treatment. The complete abstracts are available on the Congress Web site.
www.msmontreal.org, under Program.

    
            OVERVIEW OF HOT TOPICS FROM DAILY SCIENTIFIC SESSIONS

       Specific Select Daily Highlights with Presenters Available from the
                       Press Officer, Arney Rosenblat

                        Wednesday, September 17, 2008

    - Young Researchers Sessions - Including new work on identifying MS
    predictors and the implication of low levels of Vitamin D in children who
    develop MS at 14.45

    - Atlas of Multiple Sclerosis Launch - This is the most comprehensive
    study ever undertaken of the occurrence of multiple sclerosis around the
    world. The study focuses on the the global prevalence of MS and the
    resources available to diagnose, inform, treat, rehabilitate and support
    people with MS worldwide. More than 100 countries, representing almost
    88% of the world's population, participated in the study, undertaken by
    the World Health Organization and the Multiple Sclerosis International
    Federation, at 19:00, Room 516A

                         Thursday, September 18, 2008

    - Neurodegneration and inflammation - including presentations on
    reductions in brain volume across disease types, and nervous system
    repair/protection at 10.30-12.00

    - Brain plasticity and repair - including reports on mesenchymal stem
    cell injections (from patient's own bone marrow) at 14.00-15.30

    - Pediatric MS - including studies on how age modifies MS profile,
    symptoms, and disease course at 15.30- 17.45

    - Costs and Availability of MS Treatments - including generics and
    biosimilar therapies at 17.00 - 17.45

    - Genomics and Proteomics in Understanding MS - including whether
    different disease courses display different genetic architecture and
    specific proteins influence MS relapses and remissions at 17.00 -17.45

    - Emerging Therapies posters - including studies on low-dose Naltrexone,
    a drug normally used to combat addiction, and its potential in
    preventing, delaying or reducing the severity of MS at 15.30 - 17.00

                         Friday, September 19, 2008

    - Advances in imaging techniques - including metrics that might predict
    clinical disability at 10.30 - 12.00

    - Emerging Therapies - including an overview of oral and IV treatments in
    MS (14.00), studies on alemtuzumab's effect on reducing relapse rates vs.
    standard interferon (14.40), the results of a one year trial of a T-cell
    vaccination, Tovaxin, (14.55), and the first results from an early human
    trial of injections of mesenchymal stem cells (15.10)

    - Bone Marrow Transplantation - pros and cons at 17.00 - 17.45

    - Novel Cytokine, Chemokine and Adhesion Molecules - including adhesion
    molecules of the blood brain barrier and immunologic and clinical
    behavior in parasitic infection at 17.00 - 17.45

    - Better Understanding MS Disease Activity posters - including research
    examining why MS is usually more aggressive in the African-American
    population (15.30), and a study showing evidence that a gene linked to
    pain perception in healthy adults may also underlie differences in pain
    perception experienced by people with MS (15.30).

    - Possible MS Risk Factors posters - including a presentation focusing on
    latitudinal variation of sun exposure in the incidence of MS which
    explores the question of whether exposure to sunlight can protect people
    from developing MS (15.30)

    - Pediatric MS posters - including a study indicating that as many as 70%
    of children diagnosed with MS had psychiatric disorders in addition to
    MS, and a report that African-American children with MS in general
    experience more severe disease than children with MS from other racial or
    ethnic groups (15.30).

    - Emerging Therapies posters - includes a report on rituximab and its
    ability to treat breakthrough disease in people still taking a standard
    MS therapy (15.30)

                         Saturday, September 20, 2008

    Late Breaking News on Emerging Therapies - including

    - rituximab a report that focuses on possible clues to the drug's
    beneficial activity in an unsuccessful trial in the more rare primary-
    progressive form of the disease at 8.30

    - a proof-of-concept study of the first antisense approach in MS, ATL1102
    that shows significant reduction in the accumulation of new brain lesions
    at 9.15

    - Low-dose Naltrexone poster that suggests it improved mental, but not
    physical, quality of life in people with MS at 10.00

    - Fampridine poster will present the results of a Phase 3 trial showing
    that the therapy could temporarily improve walking speed and leg
    strength. This is the first time the results of the 9-week trial, which
    will serve as the basis of an application for approval, will be presented
    to a public medical audience at 10.00

    WHERE: Palais des Congrès de Montréal, 1001 Place Jean-Paul-Riopelle or
    201 Viger Ave. West
    September 17-20, from 8.30 - 17.30 Wed, Thur., Fri, and 8.30 - 10.30
    Saturday

    Assistance is available to reporters seeking to speak with specific study
presenters, conference representatives or people with MS and their families
who might be impacted by particular study results.
    




For further information:

For further information: Arney Rosenblat, Associate, vp public affairs,
National MS Society, Mobile: (917) 613-5711 (from 9/15 - 9/26),
arney.rosenblat@nmss.org, Press Room 521B, www.msmontreal.org

Organization Profile

WORLD CONGRESS ON TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890